SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as retail sentiment turned extremely bullish into the company's upcoming fiscal Q2 earnings report, after an analyst note argued BlackBerry's historically conservative guidance sets up revenue, EBITDA and EPS to come in above consensus; street models center on roughly $145.5 million in revenue, up about 12% year over year. The bull case leans heavily on QNX: traders are watching whether a newly discussed design win starts showing up in the roughly $950 million QNX royalty backlog  which management previously said contained no contribution from that win  and they cite NVIDIA's adoption of QNX 8.0 for automotive and physical AI operating systems, a SiftQNX telemetry partnership, and BlackBerry IVY partnerships as signs of the platform's expanding reach. The conversation is split, with bears repeatedly calling to short every pop and pointing to TSX short interest, while longs frame the setup as a potential squeeze with speculative price targets well above current levels.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding's steep post-earnings slide is dominating the conversation. Traders are reacting to a Q2 report showing revenue of CHF 850.3M versus roughly CHF 879.6M consensus, with EPS of CHF 0.35 narrowly beating the CHF 0.34 estimate, alongside a cut to the growth outlook that traders say management framed as protecting price integrity. The response was a record single-day drop for the name and a slide to 52-week lows, and the community is split: many call the selloff an overreaction for what they view as the sector's fastest-growing, best-margin company, while others argue the guidance cut confirmed weaker demand, fault management credibility, and note short sellers and put buyers have been consistently on the winning side. Debate continues over whether the decline is company-specific or part of broader sportswear weakness and industry-wide discounting hitting Nike, Lululemon, and Deckers. Two follow-on catalysts drew attention but little market enthusiasm: Kylian Mbapp's signing from Nike  debated as a game-changing entry into football versus an expensive bet  and an investor-day update setting 2029 financial targets plus a $1 billion buyback, which some traders see as deliberately conservative and spread over more than three years, limiting its near-term EPS impact.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is trending after its new Muse AI agent posted rapid early adoption, topping U.S. app store charts and securing a Shopify partnership, fueling a double-digit rally that traders attribute to a mix of genuine consumer demand, short covering, and options-driven gamma squeeze. The community is split: bulls see Muse as early proof that Meta's heavy AI spending is paying off, while skeptics dismiss the move as an overbought hype pump with unproven monetization and cite Amazon blocking Muse from its store as a risk, with some expecting profit-taking or a sell-the-news reaction around the upcoming Meta Connect conference.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR is trending around the Clarity Act after a Senate vote to open debate on the crypto market-structure bill fell short, leaving SEC/CFTC jurisdiction  and potential commodity treatment for tokens like HBAR  unresolved. Traders tied a quick spike-and-fade in the token to the vote, split between bulls who see regulatory clarity as the token's key catalyst and skeptics who dismissed the move as a news-driven pump followed by selling, with some blaming market makers and several posts faulting Senate Democrats and a handful of Republicans for the failed vote. A smaller thread cited Grayscale's withdrawal of its HBAR ETF filing as a reason for weakness. Meanwhile, longer-term holders pointed to fundamentals  MainNet accounts approaching 10 million, SpaceDev joining the Hedera Council, and ISO 20022 relevance  against bears flagging failed resistance near $0.08 and a rising 200-day MA around $0.068 as the next technical test.

BlackBerry's QNX is dominating the conversation, with traders focused on its expansion into physical AI and robotics and its ties to NVIDIA. Posts celebrate NVIDIA signing up QNX 8.0 for automotive and physical AI operating systems, and debate whether certification across NVIDIA's robotics platforms would dramatically enlarge the addressable market. The prevailing bull framing is that robotics, medical, and other safety-critical verticals represent an expansion of QNX beyond automotive rather than a pivot, built on its real-time, deterministic, safety-certified edge over Linux. Mentions of a Momenta autonomous-driving collaboration, BMW partnership highlights, and speculation about additional OEM wins that could push the QNX backlog toward $1 billion add to the enthusiasm; one poster claims a short attack followed news of QNX SDP 8.0 expanding in China. A strong secondary thread is the September-quarter earnings report: the community is questioning the muted earnings-date announcement, cites a revenue consensus near $142.54 million, and is split between expectations of a clean quarter and skepticism over single-digit growth guidance. Bulls also circulate short-interest data showing a slight decline and claim shorting has become costly, while critics counter that the stock's weakness is justified and that only management, debenture holders, and shorts are profiting. Sharp retail infighting over individual trading claims runs throughout the board.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD's surge into the $1 trillion market cap club is the dominant topic, with traders noting the stock has joined Nvidia, Broadcom and Micron among trillion-dollar U.S. companies after a run they estimate has added roughly $300 billion in market value as part of a broader AI-chip rally lifting peers like Intel, Arm and Micron. Reaction is sharply divided: many are celebrating the milestone and warning that shorting the momentum is a mistake, describing squeeze-like conditions and FOMO around the round-number milestone, while skeptics call the move a casino-like market detached from fundamentals  citing the share price against modest EPS, some traders expecting valuation-driven downgrades, and complaints that the rally has come on limited fresh news beyond AI-chip optimism and the OpenAI partnership, including its low-strike warrants. A recurring debate is whether the stock near $600 is a short opportunity or a trap, and some traders attribute the relentless rise to hedge fund and market-maker manipulation.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk shares are trending on a sharp sell-off, with traders debating whether the company's Capital Markets Day (CMD 2026)  where management guided to mid-single-digit revenue growth and emphasized diversifying beyond semaglutide  explains the decline, or whether the drop is disconnected from the updates. Bears in the discussion fault management for losing GLP-1 market share while over-relying on one franchise, dismissed the rebrand to 'Novo' as tone-deaf amid the slide, and pointed to bearish analyst downgrades and mounting pricing/competition pressure, with some arguing the market simply 'hates' the company and its CEO. Bulls counter that the sell-off has 'no basis,' citing a single-digit P/E at a historical low, an oral Wegovy launch that appears to be expanding the obesity market rather than cannibalizing injectables, and the view that obesity treatment is less winner-take-all than assumed. NVO's underperformance versus Eli Lilly  down more than 17% versus Lilly's 6.7% gain  frames the bear case, though dip-buying keeps sentiment sharply divided.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is trending amid a broad crypto rebound that traders attribute to massive short liquidations across the market  frequently cited at over $1.4 billion  fueling short-squeeze hype and debate over whether the memecoin follows BTC and ETH higher, while bearish posters dismiss the move and continue shorting it.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

MAGS is trending on a debate over the health of mega-cap tech leadership, with the Magnificent Seven ETF acting as the market's concentration barometer. Bulls point to a confirmed breakout, strength among hyperscalers during rotation within tech, and claims the group is 'single handedly saving the nasdaq,' arguing the indexes turn around when these names do. Bears counter with technical warnings  traders flagging MAGS below its 50-day and 200-day moving averages, roughly 10% off highs, and a possible head-and-shoulders pattern  alongside concentration concerns that a handful of companies are floating the market and the economy. The AI capex debate following mega-cap earnings, laggards versus leaders within the group, and questions over whether QQQ growth is sustainable without MAGS participation round out the discussion.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

Conversation around NUAI is dominated by anticipation of a power purchase agreement (PPA) and a potential hyperscaler lease for its Texas data-center project. Traders are split: some claim the PPA is already locked in the company's name  one cites a Vistra power agreement as the material catalyst  while others insist no tenant or PPA announcement has actually landed, with several questioning why the stock moved sharply without confirmed lease news. Bulls frame the PPA as transformative, citing the site's ~1.5 GW scale, Phase 1 development, Macquarie financing, and comparisons to CoreWeave and Applied Digital's re-ratings, alongside short-squeeze speculation around what they describe as heavy short interest and alleged market-maker manipulation. Bears counter that the company generated only tens of thousands of dollars of revenue in a recent quarter against roughly $20 million in quarterly losses and a ~$500650 million market cap, with the facility not yet operational, warning the hype will fade or lead to dilution. Debate over whether BlackRock's reported stake is a conviction bet or passive index exposure adds further speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VERAXA Biotech (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed Raju Willener as chief financial officer, adding a finance executive with more than three decades of international capital-markets experience as the biotechnology company works to advance its oncology pipeline. The appointment is effective immediately. Willener will report to Chief Executive Officer [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) is developing a new generation of antibody-based cancer therapies at a time when oncology research is increasingly focused on a difficult question: how can powerful treatments be made more selective without sacrificing their ability to kill cancer cells? The wiss biotechnology company is approaching that problem through a portfolio of antibody-drug [&#8230;]

VERAXA Biotech Designates Raju Willener as CFO

VERAXA Biotech Designates Raju Willener as CFO...

VERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer

VERAXA Biotech (NASDAQ: VRXA)&#160;a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience spanning global capital markets, investment banking, corporate finance, asset management and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, [&#8230;]

VERAXA Biotech (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, have reached an early research milestone in their collaboration to develop antibody oligonucleotide conjugates (“AOCs”), providing VERAXA with an initial proof point for applying its […]

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has moved its VXA-222 bispecific antibody-drug conjugate program into the next stage of development after completing the initial phase of its collaboration with OmniAb, giving the biotechnology company a new development milestone while it continues expanding the intellectual-property estate underpinning its antibody technology [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is advancing its oncology pipeline with a strategy centered on changing how antibody-based therapies recognize and attack cancer cells. The biotechnology company is developing bispecific antibody-drug conjugates, T-cell engagers and other engineered antibody formats, with its proprietary BiTAC technology providing the distinctive element [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies

VERAXA (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached another development milestone in its oncology pipeline, announcing that its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program has advanced beyond the discovery phase and into the next stage of development. The milestone reflects continued progress across the company’s therapeutic portfolio as it simultaneously […]

VERAXA Biotech (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics researcher Christoph Erkel, Ph.D., as Chief Scientific Officer, reinforcing the company’s focus on advancing its proprietary BiTAC(R) technology platform as it prepares its lead oncology programs for clinical development. The announcement comes at a time when the biotechnology company [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms

VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 […]

Veraxa Biotech Holding AG engages in operating an oncology-focused biotechnology company, which is the Veraxa Biotech AG (Company). The Company focuses on the development of novel antibody-based drug platforms for the treatment of cancer. The company was founded on June 25, 2025 and is headquartered in Zurich, Switzerland.

Veraxa Biotech AG

Neutral Sentiment

Rising interest rates

Surging bond yields

Oil/energy volatility

Trump/political risk

U.S. investors are navigating a stacked macro backdrop, with the Federal Reserve hiking rates for the first time since July 2023, the 10-year Treasury yield hitting 5.00% - its highest level since 2007 - and oil prices swinging between $94 and $105 a barrel amid the ongoing U.S.-Iran conflict and Saudi pipeline disruptions. What's the biggest risk to your portfolio right now? Vote and explain your reasoning in the comments.

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what&#39;s the biggest risk to your portfolio right now?

Stocktwits

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what's the biggest risk to your portfolio right now?

Current Price	$1.42
Prev Close	$1.46
Open	$1.45
Dividend Yield	0.00%
50-Day Moving Average	$1.78
Beta	0.56
Avg. Volume	158,981.55
PE Ratio	6.63

52-Week High	$27.36
52-Week Low	$1.27
Market Capitalization	$215.69M
EPS (Annual)	$0.2842
Price to Book	-0.63
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

VRXA Fundamentals